Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (ASX:IMU) enters into a research collaboration with NeoImmmuneTech to evaluate its allogeneic CAR T, azer-cel
- The partnership will use NIT’s proprietary immune T-cell amplifier “Fc-fused recombinant human interleukin-7”, NT-I7, for the treatment of cancer
- NT-I7 plays a crucial role in enhancing T cell development and survival, promoting the health and functionality of cancer-fighting T cells
- IMU shares last traded at 9.3 cents
Imugene (ASX:IMU) has entered into a strategic research collaboration with clinical-stage immuno-oncology company, NeoImmmuneTech (NIT).
The partnership will evaluate Imugene’s allogeneic CAR T, azer-cel, in combination with NIT’s proprietary immune T-cell amplifier “Fc-fused recombinant human interleukin-7”, NT-I7, for the treatment of cancer. Combining the two has the potential to increase the number of cancer-fighting properties in the body.
T cells are responsible for fighting off foreign invaders, and these will be evaluated during preclinical work.
“We are delighted to be working with NIT on the potential to enhance azer-cel activity as part of this research collaboration,” IMU Managing Director and CEO Leslie Chong said.
NT-I7 plays a crucial role in enhancing T cell development and survival, promoting the health and functionality of cancer-fighting T cells. It exhibits favourable stability, activity, and safety profiles for patient dosing, making it an ideal partner for cell therapy drugs like azer-cel, potentially improving cancer-fighting benefits.
IMU shares last traded at 9.3 cents.
